--- title: 'Life Sciences Daily Summary: What Happened on October 16, 2026' headline: Osivax misses flu-vaccine target as AstraZeneca and insitro sign discovery deal description: OVX836 produced a nonsignificant efficacy estimate of 24% in Phase 2b. AstraZeneca will pay insitro $40 million upfront for work on liver disease and cardiomyopathies. url: https://thebench.bio/news/summaries/2026-10-16 topic: all date: '2026-10-16' covers: - '2026-10-16' date_published: '2026-10-17T00:04:26Z' date_modified: '2026-10-17T00:04:26Z' tags: - Software - Clinical sources: 3 publisher: TheBench.Bio --- # Life Sciences Daily Summary: What Happened on October 16, 2026 **Osivax misses flu-vaccine target as AstraZeneca and insitro sign discovery deal** OVX836 produced a nonsignificant efficacy estimate of 24% in Phase 2b. AstraZeneca will pay insitro $40 million upfront for work on liver disease and cardiomyopathies. ## Today in brief Osivax’s OVX836 flu vaccine missed its Phase 2b efficacy target, with an estimate of 24% that was not statistically significant. [1] AstraZeneca and insitro signed a drug-discovery deal for MASH and cardiomyopathies, with $40 million upfront and about $1.46 billion in potential milestone payments. [2] ## Osivax turns to vaccine combinations after OVX836 misses its Phase 2b target OVX836 had estimated efficacy of 24% in Osivax’s Phase 2b trial, below its predefined 50% target, and the result was not statistically significant. [1] The randomized, placebo-controlled Asuniva study enrolled 2,850 healthy adults aged 18 to 59 in Belgium, France, Finland and Germany. [1] None of the reported efficacy estimates showed statistically significant protection: 28% against CDC-defined influenza-like illness, 27% against influenza A/H3 and 25% against A/H1N1pdm09. [1] The vaccine had a favorable safety profile and prompted antibody and T-cell responses against influenza nucleoprotein, the viral protein OVX836 targets. [1] Osivax is emphasizing OVX836 as a possible addition to seasonal flu vaccines, rather than mainly as a standalone alternative. [1] The company plans to advance combination candidates through two partnerships, including an August agreement with GC Biopharma for a single-injection vaccine combining OVX836 and GC FLU. [1] Osivax has not set a date for the next efficacy trial. [1] ## AstraZeneca and insitro link AI drug discovery to up to $1.46 billion in milestones AstraZeneca and insitro will use insitro’s Virtual Human platform to identify targets and develop potential therapies for metabolic dysfunction-associated steatohepatitis (MASH) and cardiomyopathies. [2] [3] insitro says the platform uses large-scale human and cellular data to identify disease biology. [2] AstraZeneca will pay $40 million upfront and could pay about $1.46 billion in development and commercial milestones for exclusive worldwide rights to selected programs. [2] [3] insitro may also receive single-digit royalties on sales if any resulting drugs reach the market. [2] [3] AstraZeneca will lead clinical development and regulatory work, while insitro advances targets selected by AstraZeneca toward development candidates. [3] AstraZeneca is testing its MASH drug AZD2389 in Phase II and discontinued AZD2693 after weak Phase II results. [2] ## The day in numbers - **24%**: OVX836’s estimated efficacy in the Phase 2b flu-vaccine trial, below its 50% target and not statistically significant. [1] - **$40 million**: Upfront payment AstraZeneca will make to insitro in their discovery and licensing deal. [2] [3] - **About $1.46 billion**: Potential development and commercial milestone payments to insitro, in addition to the upfront payment. [2] [3] ## Sources 1. [Osivax misses Phase 2b flu vaccine endpoint, shifts focus to combinations](), European Biotechnology, 2026-10-16 2. [AstraZeneca and insitro forge $1.5bn AI-powered cardiometabolic partnership ](), Pharmaceutical Technology, 2026-10-16 3. [AstraZeneca Taps insitro AI for MASH in Deal Worth Up to $1.5 Billion](), Pharmaceutical Executive, 2026-10-15 --- TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing. [1]: [2]: [3]: